{"title":"地匹福林（Corsuva）","authors":"None CADTH","doi":"10.51731/cjht.2023.745","DOIUrl":null,"url":null,"abstract":"
 CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
 The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
 This review assesses difelikefalin (Korsuva), 50 mcg/mL, IV.
 Indication: For the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult patients on hemodialysis.
","PeriodicalId":9437,"journal":{"name":"Canadian Journal of Health Technologies","volume":"40 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Difelikefalin (Korsuva)\",\"authors\":\"None CADTH\",\"doi\":\"10.51731/cjht.2023.745\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"
 CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
 The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
 This review assesses difelikefalin (Korsuva), 50 mcg/mL, IV.
 Indication: For the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult patients on hemodialysis.
\",\"PeriodicalId\":9437,\"journal\":{\"name\":\"Canadian Journal of Health Technologies\",\"volume\":\"40 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-09-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Canadian Journal of Health Technologies\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.51731/cjht.2023.745\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Canadian Journal of Health Technologies","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.51731/cjht.2023.745","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
& # x0D;CADTH报销审查是对药物或药物类别的临床有效性和成本效益以及患者和临床医生观点的综合评估。
评估结果提供了非约束性建议，这些建议有助于指导加拿大联邦、省和地区政府(魁北克省除外)的报销决定。本综述评估了difelikefalin (Korsuva)， 50 mcg/mL, IV.
适应症:用于成人血液透析患者伴慢性肾脏疾病的中重度瘙痒。
CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
This review assesses difelikefalin (Korsuva), 50 mcg/mL, IV.
Indication: For the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult patients on hemodialysis.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
